Cargando…
Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial
INTRODUCTION: COVID-19 has caused morbidity, hospitalisations and deaths worldwide. Despite four approved vaccines for COVID-19 in Canada, there is still a need for effective treatments, especially for people in the community. Vaccine efficacy is not 100% and long-term efficacy is still unknown. Fur...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895416/ https://www.ncbi.nlm.nih.gov/pubmed/35241474 http://dx.doi.org/10.1136/bmjopen-2021-057024 |
_version_ | 1784662920543600640 |
---|---|
author | Legacy, Mark Seely, Dugald Conte, Ellen Psihogios, Athanasios Ramsay, Tim Fergusson, Dean A Kanji, Salmaan Simmons, John-Graydon Wilson, Kumanan |
author_facet | Legacy, Mark Seely, Dugald Conte, Ellen Psihogios, Athanasios Ramsay, Tim Fergusson, Dean A Kanji, Salmaan Simmons, John-Graydon Wilson, Kumanan |
author_sort | Legacy, Mark |
collection | PubMed |
description | INTRODUCTION: COVID-19 has caused morbidity, hospitalisations and deaths worldwide. Despite four approved vaccines for COVID-19 in Canada, there is still a need for effective treatments, especially for people in the community. Vaccine efficacy is not 100% and long-term efficacy is still unknown. Furthermore, there are challenges to herd immunity including vaccine hesitancy and underlying conditions preventing vaccination. We aim to explore if the nutrients vitamin C, vitamin D, vitamin K(2) and zinc are an effective treatment option for outpatients diagnosed with COVID-19. The primary outcome is the difference in participant-reported overall health; secondary outcomes include the effect on health status, symptom severity and duration, frequency and length of hospitalisations and mortality. METHODS AND ANALYSIS: This study is a two-arm, parallel-group, double-blind, placebo-controlled, phase III randomised controlled trial. 200 patients will be recruited remotely from COVID-19 test centres in Ottawa, Canada associated with The Ottawa Hospital. Overall health will be measured using the EuroQol Visual Assessment Scale; health status will be measured using the EuroQol 5-dimension 5-level questionnaire; symptom severity and duration will be measured using an independently developed questionnaire; analyses will use an area under the curve approach and compare mean scores using unadjusted t tests. Study data will be recorded on electronic case report forms using the Research Electronic Data Capture platform. An independent data safety and monitoring board will perform ongoing review of the study for feasibility and safety. ETHICS AND DISSEMINATION: This study has received ethical approval from the research ethics boards of the Canadian College of Naturopathic Medicine and the Ottawa Health Sciences Network, as well as regulatory approval from the Therapeutic Products Directorate and Natural and Non-Prescription Health Products Directorate of Health Canada. Results will be published in a peer-reviewed scientific journal with open access. TRIAL REGISTRATION NUMBER: NCT04780061. |
format | Online Article Text |
id | pubmed-8895416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-88954162022-03-04 Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial Legacy, Mark Seely, Dugald Conte, Ellen Psihogios, Athanasios Ramsay, Tim Fergusson, Dean A Kanji, Salmaan Simmons, John-Graydon Wilson, Kumanan BMJ Open Complementary Medicine INTRODUCTION: COVID-19 has caused morbidity, hospitalisations and deaths worldwide. Despite four approved vaccines for COVID-19 in Canada, there is still a need for effective treatments, especially for people in the community. Vaccine efficacy is not 100% and long-term efficacy is still unknown. Furthermore, there are challenges to herd immunity including vaccine hesitancy and underlying conditions preventing vaccination. We aim to explore if the nutrients vitamin C, vitamin D, vitamin K(2) and zinc are an effective treatment option for outpatients diagnosed with COVID-19. The primary outcome is the difference in participant-reported overall health; secondary outcomes include the effect on health status, symptom severity and duration, frequency and length of hospitalisations and mortality. METHODS AND ANALYSIS: This study is a two-arm, parallel-group, double-blind, placebo-controlled, phase III randomised controlled trial. 200 patients will be recruited remotely from COVID-19 test centres in Ottawa, Canada associated with The Ottawa Hospital. Overall health will be measured using the EuroQol Visual Assessment Scale; health status will be measured using the EuroQol 5-dimension 5-level questionnaire; symptom severity and duration will be measured using an independently developed questionnaire; analyses will use an area under the curve approach and compare mean scores using unadjusted t tests. Study data will be recorded on electronic case report forms using the Research Electronic Data Capture platform. An independent data safety and monitoring board will perform ongoing review of the study for feasibility and safety. ETHICS AND DISSEMINATION: This study has received ethical approval from the research ethics boards of the Canadian College of Naturopathic Medicine and the Ottawa Health Sciences Network, as well as regulatory approval from the Therapeutic Products Directorate and Natural and Non-Prescription Health Products Directorate of Health Canada. Results will be published in a peer-reviewed scientific journal with open access. TRIAL REGISTRATION NUMBER: NCT04780061. BMJ Publishing Group 2022-03-03 /pmc/articles/PMC8895416/ /pubmed/35241474 http://dx.doi.org/10.1136/bmjopen-2021-057024 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Complementary Medicine Legacy, Mark Seely, Dugald Conte, Ellen Psihogios, Athanasios Ramsay, Tim Fergusson, Dean A Kanji, Salmaan Simmons, John-Graydon Wilson, Kumanan Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial |
title | Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial |
title_full | Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial |
title_fullStr | Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial |
title_full_unstemmed | Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial |
title_short | Dietary supplements to reduce symptom severity and duration in people with SARS-CoV-2: study protocol for a randomised, double-blind, placebo controlled clinical trial |
title_sort | dietary supplements to reduce symptom severity and duration in people with sars-cov-2: study protocol for a randomised, double-blind, placebo controlled clinical trial |
topic | Complementary Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895416/ https://www.ncbi.nlm.nih.gov/pubmed/35241474 http://dx.doi.org/10.1136/bmjopen-2021-057024 |
work_keys_str_mv | AT legacymark dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial AT seelydugald dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial AT conteellen dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial AT psihogiosathanasios dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial AT ramsaytim dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial AT fergussondeana dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial AT kanjisalmaan dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial AT simmonsjohngraydon dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial AT wilsonkumanan dietarysupplementstoreducesymptomseverityanddurationinpeoplewithsarscov2studyprotocolforarandomiseddoubleblindplacebocontrolledclinicaltrial |